CannIntelligence open content

Could cannabis help improve outcomes for patients badly afflicted by Covid?

Written by CannIntelligence | 18th August 2022

A study published this month provides further evidence that cannabis could be helpful in treating severe late-stage Covid-19 ...

Trouble in Lima – hemp bill’s chances tied up in Peru’s congressional crisis

Written by Freddie Dawson | 10th August 2022

New legislation has been put forward in Peru to establish a framework for the production and commercialisation of hemp – but what are its chances of passing in a period of political turmoil? ...

US DEA makes U-turn on psychedelics as senators call for more research support

Written by Lorraine Mullaney | 8th August 2022

The US Drug Enforcement Administration (DEA) has withdrawn its proposal to effectively ban five psychedelic compounds after receiving significant opposition from the research and advocacy community ...

In a world of wide-boys and no-hopers, who should have a licence to sell weed?

Written by Freddie Dawson | 4th August 2022

It’s difficult to get a licence to operate in the cannabis field in the US if you’ve been convicted of selling cannabis before it was legal. Yet such restrictions do little to protect the market...

Spain’s first medical cannabis regulation could boost sector despite restrictions

Written by Tiziana Cauli | 29th July 2022

Patients in Spain will soon be able to access cannabis in pharmacies with a medical prescription as the government is about to introduce new legislation ...

CBD industry warned about new intoxicating cannabinoids shaking up the market

Written by CBD-Intel | 25th July 2022

FOR IMMEDIATE RELEASE CBD industry warned about new intoxicating cannabinoids shaking up the market Consumers have an increasing appetite for cannabinoids that have a more intoxicating effect, which is shaking up the US CBD...

US 0.3% THC limit challenge dismissed: what could it mean for hemp producers?

Written by CannIntelligence | 15th July 2022

Hemp producers have lost an important challenge on the 0.3% THC threshold for hemp-derived products in the US, potentially making producers liable if they go over the threshold during production, whether or not the end...

Cannabis or marijuana? Why it matters what name you (and the law) know it by

Written by Freddie Dawson | 13th July 2022

There is quite a bit of baggage in how reference is made to the Cannabis sativa plant – as demonstrated by what's behind a new change to the law in the US state of Washington...

Israeli cannabis firms expand into Europe, bringing Cookies to Vienna

Written by Lorraine Mullaney | 7th July 2022

Israeli cannabis firm InterCure is collaborating with US brand Cookies to launch Europe’s first flagship Cookies store in Vienna; meanwhile, Panaxia Labs exports to Germany from Malta ...

Why novel food rules are pushing the UK market towards cold-pressed products

Written by CannIntelligence | 4th July 2022

Companies are facing technical and marketing pros and cons as they increasingly turn to cold-press CBD extraction as a way around novel food market limitations in the UK and Ireland ...

No magic solution: EFSA ingestible CBD safety concerns won’t be resolved quickly

Written by Freddie Dawson | 1st July 2022

It looks like there will be no easy or quick solutions to addressing the data gaps the European Food Safety Authority (EFSA) requires to reach a conclusion on the safety of CBD as an ingestible...

Why the long pause? Companies question Efsa’s insistence on filling ‘data gap’

Written by Freddie Dawson | 23rd June 2022

In trying to be overly cautious on novel foods, has the European Food Safety Authority inadvertently added an extra risk to public health? ...

Canada can teach Germany about pitfalls of legalising recreational cannabis

Written by Lorraine Mullaney | 17th June 2022

Germany should plan ahead to avoid problems which have plagued governments that have already legalised recreational cannabis on top of medical cannabis ...

Lack of quality science on cannabis and pain leaves room for fake news and myth

Written by Barnaby Page | 16th June 2022

“It’s a myth that cannabis relieves pain,” declared the Daily Mail. But that is not what the study it was reporting said at all ...

How do you tell if a user is under the influence? It’s still a testing problem

Written by CannIntelligence | 14th June 2022

While cannabis use is now legal in many US states, there is as yet no reliable test to determine whether, or how far, a user may be “under the influence” ...

Can a California cannabis cultivation tax cut help some without harming others?

Written by Freddie Dawson | 9th June 2022

Could lowering taxes lead to more revenue? It’s a question that can be applied to many retail areas, from train tickets to electronics ...

EFSA puts novel food assessment on hold for applicants to provide missing data

Written by Tiziana Cauli | 7th June 2022

A hold has been placed on European novel food assessment after the European Food Safety Authority (EFSA) said it was unable to proceed due to identified knowledge gaps in safety data ...

FDA sends warnings to companies selling CBD-containing veterinary products

Written by Tiziana Cauli | 1st June 2022

The US Food and Drug Administration (FDA) has issued warnings to four companies that have sold veterinary products containing CBD ...

US at risk of missing huge opportunity in cannabis due to lack of federal reform

Written by Lorraine Mullaney | 31st May 2022

The US is in danger of being left behind the burgeoning global cannabis market because of a lack of political will to commit to any form of federal cannabis reform ...

Off the hook – research reveals youth health benefits of legalising cannabis

Written by Aidan Semmens | 31st May 2022

A six-year study of young adult behaviour reveals that when and where cannabis use is legalised, young people’s use of alcoho. and tobacco drops – and so does the use, and misuse, of pain-relieving prescription...